BioCentury
ARTICLE | Product Development

Diagnosing AD trials

Why diagnostics are key to the development of AD drugs

March 4, 2017 2:31 AM UTC

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being tested are too limited in number and too small in scope to provide the necessary tools.

After the first wave of molecules targeting beta amyloid failed in the clinic, companies began designing studies to enroll patients they believed were more likely to respond based on a confirmed diagnosis of AD and staging methods that suggested their disease had not yet passed the point of no return...